{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-006229","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.734365+00:00","generated_at":"2026-05-15T22:40:35.793222+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Monopar appoints Susan Rodriguez as Chief Commercial and Strategy Officer; NDA submission planned H1 2026","bullets":["Susan Rodriguez appointed Chief Commercial and Strategy Officer, effective March 2, 2026.","She will lead commercial strategy ahead of planned NDA submission for ALXN1840 (Wilson disease) in H1 2026.","Ms. Rodriguez previously was COO of Avadel, acquired by Alkermes for over $2 billion.","She also served as CCO of Ardelyx, establishing its first commercial organization and launching two therapies.","Over 30 years of biopharma leadership; holds MS/BS from University of Pennsylvania."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-006229","json":"https://secwatch.observer/filing/0001437749-26-006229.json","markdown":"https://secwatch.observer/filing/0001437749-26-006229.md","text":"https://secwatch.observer/filing/0001437749-26-006229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926006229/0001437749-26-006229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926006229/mnpr20260302_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:40:35.793222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}